Bone grafting is a surgical treatment used to repair serious bone fractures. Bone grafts are implanted materials that are utilised in the surgical process to aid in bone development, bone healing, and osseous reconstruction. A bone substitute is a synthetic, inorganic, or biologically organic mixture that can be utilised in place of autogenous or allogenous bone to treat a bone deficiency. Rising road traffic accidents and joint diseases, the development of biocompatible synthetic bone grafts, and increased demand for dental bone transplant treatments are some of the primary drivers driving market expansion. However, the high costs of surgery, as well as the dangers and consequences associated with bone graft treatments, are some of the factors limiting market expansion.
Rising prevalence of bone cancer is expected to fuel demand for bone grafts and substitutes market thereby supporting the global bone graft and substitutes market growth over the forecast period. For instance, according to 2017 American Society of Clinical Oncology (ASCO) estimates, around 3,450 people of all ages in the U.S. were diagnosed with primary bone cancer. Thus, new cases of bone cancer are expected to propel growth of the bone cancer treatment market in the U.S.
Although bone grafting surgeries have provided life-sustaining choices to a significant number of patients suffering from various bone disorders, the dangers connected with surgical failure and graft failure are projected to stymie market expansion throughout the projection period. For example, according to Dental-Implants-01, the typical failure rate of dental bone grafts is 5-10% due to infections and insufficient graft stability. As a result, implantation failure is likely to stifle growth in the worldwide bone graft and replacements market over the projection period.
North America is predicted to dominate the worldwide bone graft and substitutes market over the forecast period, owing to factors such as developments in bone grafting technology and bone graft and substitutes by the region's leading companies. Artoss, Inc., based in the United States, for example, used nano-biology and nanotechnology to create artificial bone grafts. NanoBone granules were introduced in 2015, followed by NanoBone SFX putty in 2016. Furthermore, Thermo Fisher Scientific Inc., EverlyWell, Inc., Lactation Lab, and OmegaQuant, LLC are some of the U.S.-based companies that provide a variety of bone transplant and alternatives in the region.
No comments:
Post a Comment